Omeros Showcases Narsoplimab Advances for TA-TMA at 2025 Tandem Meetings

Omeros Corporation's Breakthrough Presentations on Narsoplimab at 2025 Tandem Meetings

Omeros Corporation is set to showcase significant advancements in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) at the upcoming 2025 Tandem Meetings, scheduled from February 12-15, 2025, in Honolulu, Hawaii. The company will present findings from its expanded access program for narsoplimab, an investigational fully human monoclonal antibody. This program has provided critical insights into the real-world outcomes of patients suffering from TA-TMA, a serious complication that can arise after stem cell transplants. With the presentations led by esteemed researchers from prominent institutions, Omeros emphasizes its commitment to advancing patient care and enhancing treatment options for this challenging condition.

The first presentation, led by Dr. Michelle Schoettler from Emory University, focuses on the overall survival rates of 128 allogeneic transplant patients treated with narsoplimab. Scheduled for February 13, 2025, during an oral abstract session, this presentation aims to highlight the life-saving potential and efficacy of narsoplimab in a patient population that often faces dire outcomes. The findings from this study not only provide valuable data on survival rates but also contribute to the growing body of evidence supporting the use of narsoplimab as a viable treatment option for TA-TMA.

In a complementary presentation, Dr. Piyatida Chumnumsiriwath from the University of California, Irvine, will discuss outcomes from a cohort of adult TA-TMA patients who received narsoplimab after failing treatment with eculizumab. This poster session, also on February 13, 2025, aims to shed light on the challenges faced by patients who do not respond to existing therapies and the potential benefits of switching to narsoplimab. Both presentations underscore the investigational drug's role in addressing unmet medical needs in the transplant community, particularly in managing complications associated with TA-TMA.

Omeros is currently awaiting a biologics license application (BLA) decision for narsoplimab, making these findings particularly relevant as they could influence regulatory outcomes and future treatment paradigms. The company’s engagement in the Tandem Meetings aligns with its strategy to disseminate critical research findings and gather feedback from the medical community. Presentation materials will soon be available on Omeros' investor website, further supporting transparency and collaboration in the ongoing development of narsoplimab. The forthcoming presentations not only highlight Omeros' innovative approach to addressing complex medical issues but also reinforce its dedication to improving health outcomes for patients facing severe challenges post-transplant.